Bioventus BVS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.95M-77.2% | $17.32M+332% | $4.01M-56.8% | $9.27M+379% | -$3.32M-451% | ||
| $11.21M-4.2% | $11.69M+2.6% | $11.4M-5.4% | $12.05M+1.6% | $11.87M-4.4% | ||
| $3.26M-5.1% | $3.44M+8.3% | $3.18M-12.8% | $3.64M+50.9% | $2.41M+19.7% | ||
| $135K+112% | -$1.13M-938% | $135K+207% | $44K+2.3% | $43K— | ||
| $0— | $0-100% | $1K+200% | -$1K+98.8% | -$81K+72.3% | ||
| $230K-26.3% | $312K+209% | $101K-47.7% | $193K-70.3% | $650K— | ||
| -$7.32M— | —— | —— | $13.63M+251% | -$9M-255% | ||
| $2.65M+120% | -$12.97M-4,356% | -$291K-110% | $2.81M+49.3% | $1.88M-66.2% | ||
| -$15.37M-246% | -$4.44M— | —— | —— | -$39.1M-335% | ||
| $275K+77.4% | $155K-36.2% | $243K-36.4% | $382K+0.3% | $381K-69.5% | ||
| $8.93M-76.5% | $37.97M+26.1% | $30.1M+16.0% | $25.94M+234% | -$19.33M-200% | ||
| $574K-1.0% | $580K+22.6% | $473K-30.7% | $683K-17.3% | $826K+43.9% | ||
| -$574K+1.0% | -$580K-22.6% | -$473K+65.4% | -$1.37M-65.7% | -$826K-103% | ||
| $0-100% | $25M+150% | $10M+100% | $5M0.0% | $5M-66.7% | ||
| $120K-76.5% | $511K+432% | $96K-92.7% | $1.32M+778% | $150K-86.4% | ||
| $1.04M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | $10.77M+19.7% | $9M— | ||
| —— | $174.25K0.0% | $174.25K0.0% | $174.25K0.0% | $174.25K-40.9% | ||
| -$23.14M+18.6% | -$28.45M-42.4% | -$19.98M-36.2% | -$14.66M-1,648% | $947K+102% | ||
| -$608K-557% | $133K— | —— | $202K-53.0% | $430K+121% | ||
| -$15.39M-270% | $9.07M-1.9% | $9.25M-8.4% | $10.11M+154% | -$18.78M— | ||
| -$54K-300% | $27K— | $0-100% | $123K-49.2% | $242K+92.1% | ||
| $0— | $0-100% | $1K+200% | -$1K+98.8% | -$81K+72.3% | ||
| $230K-26.3% | $312K+209% | $101K-47.7% | $193K-70.3% | $650K— | ||
| —— | -$171.5K0.0% | -$171.5K0.0% | -$171.5K0.0% | -$171.5K-103% | ||
| —— | $16.44M0.0% | $16.44M0.0% | $16.44M0.0% | $16.44M— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$220K-5.8% | -$208K-0.5% | -$207K+1.0% | -$209K-3.0% | -$203K-4.6% | ||
| $0-100% | $25M+150% | $10M+100% | $5M0.0% | $5M-66.7% | ||
| $534K+2,327% | $22K0.0% | $22K-60.7% | $56K-60.0% | $140K— | ||
| $0— | —— | —— | $10.77M+19.7% | $9M— | ||
| $0— | —— | $30M— | —— | $15M— | ||
| $8.36M-77.6% | $37.39M+26.2% | $29.63M+17.3% | $25.26M+225% | -$20.16M-208% | ||
| $8.36M-77.6% | $37.39M+26.2% | $29.63M+17.3% | $25.26M+225% | -$20.16M-208% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bioventus generate?
- Bioventus (BVS) generated $102.9M in operating cash flow over the trailing twelve months.
- What is Bioventus's free cash flow?
- After $2.3M of capital expenditures, Bioventus's free cash flow was $100.6M over the trailing twelve months, up 320.5% year over year.
- Where does Bioventus's cash flow data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
